Surgery Partners (SGRY) Stock Forecast, Price Target & Predictions
SGRY Stock Forecast
Surgery Partners stock forecast is as follows: an average price target of $47.50 (represents a 53.23% upside from SGRY’s last price of $31.00) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
SGRY Price Target
The average price target for Surgery Partners (SGRY) is $47.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $64.00 to $31.00. This represents a potential 53.23% upside from SGRY's last price of $31.00.
SGRY Analyst Ratings
According to 8 Wall Street analysts, Surgery Partners's rating consensus is 'Buy'. The analyst rating breakdown for SGRY stock is 0 'Strong Buy' (0.00%), 5 'Buy' (62.50%), 3 'Hold' (37.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Surgery Partners Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Tao Qiu | Macquarie | $31.00 | $24.32 | 27.47% | - |
| May 04, 2022 | - | Citigroup | $64.00 | $53.62 | 19.37% | 106.45% |
The latest Surgery Partners stock forecast, released on Jun 28, 2024 by Tao Qiu from Macquarie, set a price target of $31.00, which represents a 27.47% increase from the stock price at the time of the forecast ($24.32), and a 0.00% decrease from SGRY last price ($31.00).
Surgery Partners Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $31.00 | $31.00 |
| Last Closing Price | $31.00 | $31.00 | $31.00 |
| Upside/Downside | -100.00% | - | - |
In the current month, the average price target of Surgery Partners stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Surgery Partners's last price of $31.00. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 19, 2024 | RBC Capital | Buy | Buy | Hold |
| Aug 19, 2024 | Raymond James | Underperform | Underperform | Hold |
| Jun 28, 2024 | Macquarie | Buy | Buy | Hold |
| Jun 28, 2024 | Macquarie | - | Outperform | Initialise |
| Mar 05, 2024 | RBC Capital | Buy | Buy | Hold |
| Nov 14, 2023 | Cowen & Co. | - | Outperform | Upgrade |
| Jun 02, 2023 | Goldman Sachs | - | Neutral | Downgrade |
| Jun 02, 2023 | Atlantic Equities | - | Neutral | Downgrade |
| Jun 02, 2023 | BTIG | - | Neutral | Downgrade |
| Jun 02, 2023 | BMO Capital | - | Outperform | Upgrade |
Surgery Partners's last stock rating was published by RBC Capital on Aug 19, 2024. The company gave SGRY a "Buy" rating, the same as its previous rate.
Surgery Partners Financial Forecast
Surgery Partners Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $735.40M | $674.10M | $667.60M | $666.20M | $707.10M | $620.60M | $615.40M | $596.20M | $610.20M | $559.20M | $543.30M | $512.40M | $548.30M | $496.10M | $374.70M | $441.00M | $517.20M | $452.00M |
| Avg Forecast | $995.88M | $900.19M | $911.29M | $876.18M | $913.87M | $831.47M | $835.22M | $801.03M | $835.88M | $768.97M | $735.94M | $698.73M | $741.45M | $671.99M | $669.43M | $656.74M | $688.06M | $633.99M | $623.90M | $576.58M | $624.38M | $543.03M | $533.43M | $494.74M | $548.64M | $462.15M | $302.26M | $405.09M | $514.93M | $452.12M |
| High Forecast | $1.01B | $912.78M | $924.04M | $888.44M | $926.66M | $843.10M | $846.91M | $812.24M | $847.57M | $772.19M | $746.23M | $708.50M | $743.58M | $681.39M | $678.80M | $665.92M | $697.68M | $642.86M | $633.44M | $585.39M | $633.92M | $551.33M | $541.58M | $502.30M | $557.03M | $469.21M | $306.88M | $411.28M | $522.80M | $459.03M |
| Low Forecast | $980.46M | $886.25M | $897.18M | $862.61M | $899.72M | $818.59M | $822.29M | $788.63M | $822.94M | $767.38M | $724.54M | $687.91M | $737.22M | $661.59M | $659.07M | $646.57M | $677.40M | $624.17M | $613.73M | $567.18M | $614.20M | $534.18M | $524.74M | $486.68M | $539.70M | $454.62M | $297.33M | $398.49M | $506.54M | $444.75M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 16 | 8 | 11 | 7 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.00% | 1.00% | 1.01% | 1.03% | 0.98% | 0.99% | 1.03% | 0.98% | 1.03% | 1.02% | 1.04% | 1.00% | 1.07% | 1.24% | 1.09% | 1.00% | 1.00% |
Surgery Partners's average Quarter revenue forecast for Mar 24 based on 4 analysts is $698.73M, with a low forecast of $687.91M, and a high forecast of $708.50M. SGRY's average Quarter revenue forecast represents a -4.99% decrease compared to the company's last Quarter revenue of $735.40M (Dec 23).
Surgery Partners EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 16 | 8 | 11 | 7 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $35.10M | $11.90M | $26.60M | $106.10M | $169.80M | $118.60M | $113.80M | $102.00M | $71.82M | $57.70M | $49.00M | $58.20M | $79.40M | $15.30M | $39.50M | $26.20M | $21.40M | $79.60M |
| Avg Forecast | $192.26M | $173.79M | $175.93M | $169.15M | $176.43M | $160.52M | $161.25M | $154.65M | $161.37M | $148.46M | $142.08M | $69.13M | $143.14M | $129.73M | $129.24M | $62.84M | $132.83M | $56.42M | $120.45M | $57.13M | $120.54M | $104.84M | $102.98M | $69.21M | $105.92M | $89.22M | $58.35M | $33.84M | $99.41M | $87.29M |
| High Forecast | $194.95M | $176.22M | $178.39M | $171.52M | $178.90M | $162.77M | $163.50M | $156.81M | $163.63M | $149.08M | $144.07M | $82.95M | $143.55M | $131.55M | $131.05M | $75.41M | $134.69M | $67.70M | $122.29M | $68.56M | $122.38M | $106.44M | $104.56M | $83.05M | $107.54M | $90.59M | $59.25M | $40.61M | $100.93M | $88.62M |
| Low Forecast | $189.29M | $171.10M | $173.21M | $166.53M | $173.70M | $158.04M | $158.75M | $152.25M | $158.87M | $148.15M | $139.88M | $55.30M | $142.33M | $127.72M | $127.24M | $50.28M | $130.78M | $45.13M | $118.49M | $45.71M | $118.58M | $103.13M | $101.30M | $55.37M | $104.19M | $87.77M | $57.40M | $27.07M | $97.79M | $85.86M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.25% | 0.09% | 0.21% | 1.69% | 1.28% | 2.10% | 0.94% | 1.79% | 0.60% | 0.55% | 0.48% | 0.84% | 0.75% | 0.17% | 0.68% | 0.77% | 0.22% | 0.91% |
4 analysts predict SGRY's average Quarter EBITDA for Mar 24 to be $69.13M, with a high of $82.95M and a low of $55.30M. This is 96.95% upper than Surgery Partners's previous annual EBITDA (Dec 23) of $35.10M.
Surgery Partners Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 16 | 8 | 11 | 7 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $58.70M | $35.90M | $42.10M | $1.20M | $23.30M | $5.60M | $15.30M | $42.80M | $42.90M | $-22.90M | $-26.90M | $-21.00M | $5.50M | $-61.60M | $-32.50M | $-27.50M | $-19.20M | $-15.70M |
| Avg Forecast | $88.58M | $52.05M | $38.93M | $23.14M | $70.70M | $40.25M | $32.15M | $19.61M | $60.59M | $31.68M | $25.16M | $12.08M | $47.76M | $18.05M | $10.20M | $10.98M | $25.64M | $-22.39M | $-2.44M | $9.98M | $24.45M | $-7.48M | $-19.78M | $-24.97M | $2.07M | $-47.74M | $-87.20M | $-35.52M | $15.65M | $-26.14M |
| High Forecast | $90.19M | $53.00M | $39.64M | $23.56M | $71.98M | $40.98M | $32.74M | $19.97M | $61.69M | $35.48M | $25.62M | $14.49M | $51.63M | $18.38M | $10.38M | $13.18M | $26.10M | $-17.91M | $-2.39M | $11.98M | $24.93M | $-7.32M | $-19.37M | $-19.98M | $2.11M | $-46.73M | $-85.35M | $-28.42M | $15.96M | $-25.59M |
| Low Forecast | $86.80M | $51.00M | $38.14M | $22.67M | $69.27M | $39.44M | $31.50M | $19.22M | $59.37M | $30.41M | $24.66M | $9.66M | $43.89M | $17.69M | $9.99M | $8.78M | $25.12M | $-26.87M | $-2.49M | $7.99M | $23.93M | $-7.63M | $-20.18M | $-29.97M | $2.03M | $-48.69M | $-88.93M | $-42.62M | $15.32M | $-26.66M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.23% | 1.99% | 4.13% | 0.11% | 0.91% | -0.25% | -6.27% | 4.29% | 1.75% | 3.06% | 1.36% | 0.84% | 2.66% | 1.29% | 0.37% | 0.77% | -1.23% | 0.60% |
Surgery Partners's average Quarter net income forecast for Mar 24 is $12.08M, with a range of $9.66M to $14.49M. SGRY's average Quarter net income forecast represents a -79.42% decrease compared to the company's last Quarter net income of $58.70M (Dec 23).
Surgery Partners SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 16 | 8 | 11 | 7 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $97.80M | $109.20M | $104.10M | $32.00M | $28.70M | $17.90M | $26.10M | $29.50M | $27.20M | $25.50M | $24.50M | $26.80M | $23.80M | $25.20M | $25.30M | $43.10M | $42.90M | $38.30M |
| Avg Forecast | $46.14M | $41.70M | $42.22M | $40.59M | $42.34M | $38.52M | $38.69M | $37.11M | $38.72M | $35.62M | $34.09M | $92.17M | $34.35M | $31.13M | $31.01M | $83.79M | $31.88M | $24.93M | $28.90M | $76.17M | $28.93M | $25.16M | $24.71M | $31.87M | $25.42M | $21.41M | $14.00M | $55.67M | $23.86M | $20.95M |
| High Forecast | $46.78M | $42.29M | $42.81M | $41.16M | $42.93M | $39.06M | $39.24M | $37.63M | $39.27M | $35.77M | $34.57M | $110.60M | $34.45M | $31.57M | $31.45M | $100.55M | $32.32M | $29.92M | $29.35M | $91.41M | $29.37M | $25.54M | $25.09M | $38.24M | $25.81M | $21.74M | $14.22M | $66.80M | $24.22M | $21.27M |
| Low Forecast | $45.42M | $41.06M | $41.56M | $39.96M | $41.68M | $37.92M | $38.09M | $36.54M | $38.12M | $35.55M | $33.57M | $73.74M | $34.15M | $30.65M | $30.53M | $67.03M | $31.38M | $19.95M | $28.43M | $60.94M | $28.45M | $24.75M | $24.31M | $25.50M | $25.00M | $21.06M | $13.77M | $44.54M | $23.47M | $20.60M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.85% | 3.51% | 3.36% | 0.38% | 0.90% | 0.72% | 0.90% | 0.39% | 0.94% | 1.01% | 0.99% | 0.84% | 0.94% | 1.18% | 1.81% | 0.77% | 1.80% | 1.83% |
Surgery Partners's average Quarter SG&A projection for Mar 24 is $92.17M, based on 4 Wall Street analysts, with a range of $73.74M to $110.60M. The forecast indicates a -5.76% fall compared to SGRY last annual SG&A of $97.80M (Dec 23).
Surgery Partners EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 10 | 16 | 8 | 11 | 7 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.29 | - | $0.01 | $0.23 | $0.06 | $0.17 | $0.49 | $0.51 | $-0.28 | $-0.39 | $-0.38 | $0.11 | $-1.46 | $-0.86 | $-0.57 | $-0.40 | $-0.32 |
| Avg Forecast | $0.70 | $0.41 | $0.31 | $0.18 | $0.56 | $0.32 | $0.25 | $0.16 | $0.48 | $0.25 | $0.20 | $0.07 | $0.38 | $0.14 | $0.08 | - | $0.20 | $0.05 | $-0.02 | $-0.07 | $0.19 | $-0.06 | $-0.16 | $-0.37 | $0.02 | $-0.38 | $-0.69 | $-0.45 | $0.12 | $-0.21 |
| High Forecast | $0.72 | $0.42 | $0.31 | $0.19 | $0.57 | $0.32 | $0.26 | $0.16 | $0.49 | $0.28 | $0.20 | $0.07 | $0.41 | $0.15 | $0.08 | - | $0.21 | $0.05 | $-0.02 | $-0.07 | $0.20 | $-0.06 | $-0.15 | $-0.36 | $0.02 | $-0.37 | $-0.68 | $-0.44 | $0.13 | $-0.20 |
| Low Forecast | $0.69 | $0.40 | $0.30 | $0.18 | $0.55 | $0.31 | $0.25 | $0.15 | $0.47 | $0.24 | $0.20 | $0.07 | $0.35 | $0.14 | $0.08 | - | $0.20 | $0.04 | $-0.02 | $-0.07 | $0.19 | $-0.06 | $-0.16 | $-0.38 | $0.02 | $-0.39 | $-0.71 | $-0.45 | $0.12 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 2.03% | 0.00% | 2.61% | 1.13% | 1.38% | -8.78% | -6.91% | 2.63% | 4.72% | 2.49% | 1.03% | 6.85% | 3.86% | 1.24% | 1.27% | -3.20% | 1.57% |
According to 4 Wall Street analysts, Surgery Partners's projected average Quarter EPS for Mar 24 is $0.07, with a low estimate of $0.07 and a high estimate of $0.07. This represents a 14202.00% increase compared to SGRY previous annual EPS of - (Dec 23).
Surgery Partners Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HCSG | Healthcare Services Group | $11.14 | $17.33 | 55.57% | Hold |
| SGRY | Surgery Partners | $31.00 | $47.50 | 53.23% | Buy |
| EHAB | Enhabit | $8.10 | $10.25 | 26.54% | Hold |
| SEM | Select Medical | $35.23 | $40.00 | 13.54% | Buy |
| INNV | InnovAge | $5.99 | $6.80 | 13.52% | Hold |
| EHC | Encompass Health | $93.25 | $93.17 | -0.09% | Buy |
| ADUS | Addus HomeCare | $130.13 | $123.00 | -5.48% | Buy |
| UHS | Universal Health Services | $232.56 | $208.47 | -10.36% | Hold |
| PNTG | Pennant Group | $34.52 | $30.67 | -11.15% | Buy |
| ENSG | Ensign Group | $152.73 | $114.25 | -25.19% | Buy |
SGRY Forecast FAQ
Is Surgery Partners a good buy?
Yes, according to 8 Wall Street analysts, Surgery Partners (SGRY) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 62.50% of SGRY's total ratings.
What is SGRY's price target?
Surgery Partners (SGRY) average price target is $47.5 with a range of $31 to $64, implying a 53.23% from its last price of $31. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Surgery Partners stock go up soon?
According to Wall Street analysts' prediction for SGRY stock, the company can go up by 53.23% (from the last price of $31 to the average price target of $47.5), up by 106.45% based on the highest stock price target, and down by 0% based on the lowest stock price target.
Can Surgery Partners stock reach $50?
SGRY's highest twelve months analyst stock price target of $64 supports the claim that Surgery Partners can reach $50 in the near future.
What are Surgery Partners's analysts' financial forecasts?
Surgery Partners's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.38B (high $3.43B, low $3.33B), average EBITDA is $652.84M (high $661.98M, low $642.73M), average net income is $162.71M (high $165.67M, low $159.44M), average SG&A $156.66M (high $158.85M, low $154.23M), and average EPS is $1.29 (high $1.31, low $1.26). SGRY's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.68B (high $3.74B, low $3.63B), average EBITDA is $711.14M (high $721.09M, low $700.13M), average net income is $202.69M (high $206.38M, low $198.61M), average SG&A $170.65M (high $173.04M, low $168.01M), and average EPS is $1.61 (high $1.64, low $1.57).
Did the SGRY's actual financial results beat the analysts' financial forecasts?
Based on Surgery Partners's last annual report (Dec 2023), the company's revenue was $2.74B, beating the average analysts forecast of $2.74B by 0.13%. Apple's EBITDA was $60.1M, missing the average prediction of $464.96M by -87.07%. The company's net income was $134.7M, beating the average estimation of $86.99M by 54.85%. Apple's SG&A was $417.7M, beating the average forecast of $180.28M by 131.69%. Lastly, the company's EPS was $0.0011, missing the average prediction of $0.606 by -99.82%. In terms of the last quarterly report (Dec 2023), Surgery Partners's revenue was $735.4M, missing the average analysts' forecast of $741.45M by -0.82%. The company's EBITDA was $35.1M, missing the average prediction of $143.14M by -75.48%. Surgery Partners's net income was $58.7M, beating the average estimation of $47.76M by 22.91%. The company's SG&A was $97.8M, beating the average forecast of $34.35M by 184.72%. Lastly, the company's EPS was $0.0005, missing the average prediction of $0.379 by -99.87%